Skip to main content
Medical information Clinical review pending

Genetic Testing

HSPB1 Gene CMT2F Genetic Test

Genetic test using Next-Generation Sequencing (NGS) to detect mutations in the HSPB1 gene associated with Charcot-Marie-Tooth disease type 2F (CMT2F), a hereditary neuropathy.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (typically collected in an EDTA tube). Confirm with the laboratory before booking.
Results
Confirm with the laboratory before booking.
Preparation
No specific preparation is required for this test. Patients should inform the laboratory if they are taking any medications. Confirm with the laboratory before booking.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the HSPB1 Gene CMT2F Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Symptoms suggestive of hereditary neuropathy (e.g., muscle weakness, sensory loss, foot deformities).
  • ✓Family history of Charcot-Marie-Tooth disease or related neurological disorders.
  • ✓Confirmation of suspected CMT2F diagnosis.
  • ✓Genetic counseling for individuals with CMT2F or family history.
  • ✓Assessment of risk for family members.
02

In plain language

What this test helps you understand

This test helps confirm a diagnosis of Charcot-Marie-Tooth disease type 2F (CMT2F) by identifying mutations in the HSPB1 gene. It aids in understanding the specific genetic cause of the condition, which can inform prognosis and management strategies. Results may also be useful for genetic counseling and family planning.
The HSPB1 Gene CMT2F NGS Genetic DNA Test is a diagnostic tool used to identify genetic mutations linked to Charcot-Marie-Tooth disease type 2F (CMT2F). This condition is a type of hereditary neuropathy affecting the nerves outside the brain and spinal cord, often leading to muscle weakness and sensory loss, particularly in the feet and hands.

This test utilizes advanced Next-Generation Sequencing (NGS) technology to analyze the HSPB1 gene. Mutations in this gene are known to cause CMT2F. Identifying these specific mutations can help healthcare providers understand the underlying cause of a patient's symptoms.

Understanding the genetic basis of CMT2F is crucial for accurate diagnosis, prognosis, and management. It can also provide valuable information for family members who may be at risk.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo specific preparation is required for this test. Patients should inform the laboratory if they are taking any medications. Confirm with the laboratory before booking.
SampleBlood sample (typically collected in an EDTA tube). Confirm with the laboratory before booking.
MethodologyNext-Generation Sequencing (NGS) is used to analyze the HSPB1 gene for pathogenic variants.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test specifically analyzes the HSPB1 gene. It may not detect mutations in other genes associated with CMT or other neurological conditions. A negative result does not completely rule out a genetic cause for the symptoms. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

CMT2F is a hereditary neuropathy, a condition affecting the nerves outside the brain and spinal cord, leading to symptoms like muscle weakness and sensory loss.
This test looks for specific genetic mutations in the HSPB1 gene that are known to cause CMT2F.
Individuals with symptoms of hereditary neuropathy, a family history of CMT, or those suspected of having CMT2F should discuss this test with their doctor.
A healthcare professional will interpret the results based on the clinical picture. A positive result indicates mutations linked to CMT2F. Discuss your results with your doctor.
Insurance coverage varies. Please check with your insurance provider regarding coverage for genetic testing.
You can book the test by calling or WhatsApping us at +254711564616. We have branches in major cities and offer home sample collection.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp